Cipla Receives USFDA’s Green Flag For Generic Inhaler
Amid Covid-19, Mumbai-based Cipla has received the US Food and Drug Administration’s approval to manufacture the first generic form of Albuterol Sulfate inhaler treating respiratory difficulties. It will be Cipla’s first device-based inhalation product in the market.
Soon after the pharma company announced the approval today, it's share rose to 52 weeks high of Rs 595.00 on 9 April.
Cipla is known for its respiratory segment. Furthering it, company’s Albuterol Sulfate Inhalation Aerosol will be a generic equivalent version of Proventil HFA Inhalation Aerosol of Merck Sharp & Dohme Corp. The drug is used to treat acute bronchospasm or asthmatic symptoms.
Speaking on the approval, Umang Vohra, MD and Global CEO, Cipla said, “This development reiterates our commitment of strengthening our respiratory franchise and will further solidify our position as lung leader globally. We will continue to build on our portfolio of drug-device combinations in the respiratory space to serve the unmet needs of our patients across markets.”
During the Coronavirus pandemic, the company is planning shipments in a staggered manner and donate the product.
India’s third-largest pharma company has 46 manufacturing sites around the world, produces 50+ dosage forms and 1,500+ products using cutting-edge technology platforms to cater to our 80+ markets. Apart from respiratory, they are well known in segments like anti-retroviral, urology, cardiology, anti-infective and CNS segments.
